Lipoid pneumonia historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(9 intermediate revisions by 3 users not shown)
Line 5: Line 5:


==Overview==
==Overview==
In 1925,G. F. LAUGHLEN, M.D. was  the first [[physician]] to describe [[lipoid pneumonia]]. he first interacted to the disease by routine [[autopsy]] at the Toronto, Ontorio hospital for sick children. he described grayish red nodules at the autopsy with three types of [[Exudate|exudates]], found out [[Monocyte|mononuclear]] cells which were unexpected in the [[Exudate|exudates]].
In 1925, G. F. LAUGHLEN, M.D. was  the first [[physician]] to describe [[lipoid pneumonia]]. He first interacted with the disease by routine [[autopsy]] at the Toronto, Ontario hospital for sick children. He described grayish red [[nodules]] at the [[autopsy]] with three types of [[Exudate|exudates]], found out [[Monocyte|mononuclear]] cells which were unexpected in the [[Exudate|exudates]]. In 1949 McDonald et al described [[endogenous]] [[lipoid pneumonia]] for the first time. He observed so-called "obstructive [[pneumonia]]" in patients with [[Lung cancer|lung neoplasms]].


==Historical Perspective==
==Historical Perspective==
Line 11: Line 11:
===Discovery===
===Discovery===


*In 1925,G. F. LAUGHLEN, M.D. was  the first [[physician]] to describe [[lipoid pneumonia]].<ref name="pmid19969662">{{cite journal |vauthors=Laughlen GF |title=Studies on Pneumonia Following Naso-Pharyngeal Injections of Oil |journal=The American Journal of Pathology |volume=1 |issue=4 |pages=407–414.1 |date=July 1925 |pmid=19969662 |pmc=1931653 |doi= |url=}}</ref>
*In 1925,G. F. LAUGHLEN, M.D. was  the first [[physician]] to describe [[exogenous]] [[lipoid pneumonia]].<ref name="pmid19969662">{{cite journal |vauthors=Laughlen GF |title=Studies on Pneumonia Following Naso-Pharyngeal Injections of Oil |journal=The American Journal of Pathology |volume=1 |issue=4 |pages=407–414.1 |date=July 1925 |pmid=19969662 |pmc=1931653 |doi= |url=}}</ref>
*He first interacted to the disease by routine [[autopsy]] at the Toronto, Ontorio hospital for sick children.
*He first interacted to the [[disease]] by routine [[autopsy]] at the Toronto, Ontario hospital for sick children.
*He described grayish red nodules at the autopsy with three types of [[Exudate|exudates]], found out [[Monocyte|mononuclear]] cells which were unexpected in the [[Exudate|exudates]].
*He described grayish red [[nodules]] at the [[autopsy]] with three types of [[Exudate|exudates]], found out [[Monocyte|mononuclear]] cells which were unexpected in the [[Exudate|exudates]].
*All of his 4 observed cases underwent [[laxative]] and nasal drop therapy regimen.
*All of his 4 observed cases underwent [[laxative]] and [[nasal]] drop [[therapy]] regimen.
*In 1949 McDonald et al described [[endogenous]] [[lipoid pneumonia]] for the first time.<ref name="pmid18110247">{{cite journal| author=McDONALD JR, HARRINGTON SW, CLAGETT OT| title=Obstructive pneumonitis of neoplastic origin; an interpretation of one form of so-called atelectasis and its correlation according to presence of absence of sputum. | journal=J Thorac Surg | year= 1949 | volume= 18 | issue= 1 | pages= 97-112; disc., 122 | pmid=18110247 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18110247  }}</ref>
*He observed so called "obstructive [[pneumonia]]" in patients with [[Lung cancer|lung neoplasms]].<ref name="pmid9925081" />


<br />
===Important landmark===
Following are important landmark events that shows how [[aspiration pneumonia]] became an important entity of critical care:<ref name="pmid19857224">{{cite journal| author=Japanese Respiratory Society| title=Aspiration pneumonia. | journal=Respirology | year= 2009 | volume= 14 Suppl 2 | issue=  | pages= S59-64 | pmid=19857224 | doi=10.1111/j.1440-1843.2009.01578.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19857224  }}</ref><ref name="pmid23052002">{{cite journal| author=Almirall J, Cabré M, Clavé P| title=Complications of oropharyngeal dysphagia: aspiration pneumonia. | journal=Nestle Nutr Inst Workshop Ser | year= 2012 | volume= 72 | issue=  | pages= 67-76 | pmid=23052002 | doi=10.1159/000339989 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23052002  }}</ref><ref name="pmid9925081">{{cite journal| author=Marik PE, Careau P| title=The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. | journal=Chest | year= 1999 | volume= 115 | issue= 1 | pages= 178-83 | pmid=9925081 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9925081  }}</ref><ref name="pmid23598958">{{cite journal| author=Cordier JF, Cottin V| title=Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. | journal=Eur Respir J | year= 2013 | volume= 42 | issue= 4 | pages= 916-23 | pmid=23598958 | doi=10.1183/09031936.00027913 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23598958  }}</ref><ref name="pmid29500665">{{cite journal| author=Shi X, Zheng J, Yan T| title=Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia. | journal=J Mol Model | year= 2018 | volume= 24 | issue= 4 | pages= 79 | pmid=29500665 | doi=10.1007/s00894-018-3613-z | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29500665  }}</ref><ref name="pmid28270104">{{cite journal| author=Shen CF, Wang SM, Ho TS, Liu CC| title=Clinical features of community acquired adenovirus pneumonia during the 2011 community outbreak in Southern Taiwan: role of host immune response. | journal=BMC Infect Dis | year= 2017 | volume= 17 | issue= 1 | pages= 196 | pmid=28270104 | doi=10.1186/s12879-017-2272-5 | pmc=5341368 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28270104  }}</ref>


{| class="wikitable"
!Year
!Events
|-
!460 BC–380 BC
|Hippocrates described [[pneumonia]].
|-
!1138–1204 AD
|Maimonides wrote about [[pneumonia]] as "The basic [[symptoms]] which occur in [[pneumonia]] and which are never lacking are as follows: acute [[fever]], sticking [[pleuritic pain]] in the side, short rapid [[Breath|breaths]], serrated [[pulse]], and [[cough]]."
|-
!1875
|[[Edwin Klebs]] identified [[bacteria]] in the [[Airway|airways]] of individuals who [[died]] from [[pneumonia]].
|-
!1848
|[[Carl Friedländer]] identified the two common [[bacteria]] such as ''[[Streptococcus pneumoniae]]'' and ''[[Klebsiella pneumoniae]]'' that cause [[pneumonia]].
|-
!1893
|Veillon was first to write about the role of [[Anaerobic organism|anaerobic bacteria]] in [[aspiration pneumonia]].
|-
!1896
|Roentgen described [[x-rays]].
|-
!1918
|Sir William Osler, known as "the father of modern medicine," appreciated the [[morbidity]] and [[mortality]] of [[pneumonia]], describing it as the "captain of the men of death."
|-
!1927
|Smith was first to clearly show [[Anaerobic organism|anaerobic bacterial]] growth in animal models suffered from [[aspiration pneumonia]].
|-
!1929
|Drinker and Shaw announced the invention of the [[iron lung]] during the
 [[polio]] [[epidemic]].
|-
!1985
| Specimens collected from [[Patient|patients]] with [[aspiration pneumonia]] were vastly cultured and it was called [[anaerobic]] bandwagon.
|}
=== Lipoid pneumonia outbreak ===
* During July and August 2019, five [[patients]] were identified at two hospitals in North Carolina with [[acute lung injury]] potentially associated with [[e-cigarette]] use.
* Patients were adults aged 18–35 years and all experienced several days of worsening [[dyspnea]], [[nausea]], [[vomiting]], [[abdominal discomfort]], and [[Fever and abdominal pain|fever]].
* All patients demonstrated [[tachypnea]] with increased work of [[breathing]] on [[examination]], [[hypoxemia]] ([[pulse oximetry]] <90% on room air), and [[bilateral]] [[lung]] infiltrates on [[Chest X-ray|chest x-ray]].
* All five [[Patient|patients]] shared history of recent use of [[Cannabis (drug)|marijuana]] oils or concentrates in [[E-cigarette|e-cigarettes]].<ref name="urlOutbreak of Electronic-Cigarette–Associated Acute Lipoid Pneumonia — North Carolina, July–August 2019 | MMWR2">{{cite web |url=https://www.cdc.gov/mmwr/volumes/68/wr/mm6836e1.htm?s_cid=mm6836e1_w |title=Outbreak of Electronic-Cigarette–Associated Acute Lipoid Pneumonia — North Carolina, July–August 2019 &#124; MMWR |format= |work= |accessdate=}}</ref>
* Thirty-three deaths confirmed due to vaping  in 24 states of US, but [[lipoid pneumonia]] role in those [[Mortality|mortalities]] was not proven.<ref name="urlOutbreak of Electronic-Cigarette–Associated Acute Lipoid Pneumonia — North Carolina, July–August 2019 | MMWR">{{cite web |url=https://www.cdc.gov/mmwr/volumes/68/wr/mm6836e1.htm?s_cid=mm6836e1_w |title=Outbreak of Electronic-Cigarette–Associated Acute Lipoid Pneumonia — North Carolina, July–August 2019 &#124; MMWR |format= |work= |accessdate=}}</ref>
*The higher risk of lipoid pneumonia in THC vaping was then hypothesized to be due to usage of vitamin E in THC juice of e-cigarettes.<ref name="urlCDC vaping illness investigation: Vitamin E acetate linked to THC may be to blame - CNN">{{cite web |url=https://www.cnn.com/2019/11/08/health/vaping-injury-vitamin-e-thc-bn/index.html |title=CDC vaping illness investigation: Vitamin E acetate linked to THC may be to blame - CNN |format= |work= |accessdate=}}</ref>
*Vitamin E is a substance added to cannabis products to increase their central effect.
*It's streaky and high solubility potential is said to be the cause of lipoid pneumonia.
{| align="center"
|
{{#ev:youtube|https://www.youtube.com/watch?v=BtKbUpKeU_Q|500}}
|}
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 13:25, 11 November 2019

Lipoid pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lipoid pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lipoid pneumonia historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lipoid pneumonia historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lipoid pneumonia historical perspective

CDC on Lipoid pneumonia historical perspective

Lipoid pneumonia historical perspective in the news

Blogs on Lipoid pneumonia historical perspective

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Lipoid pneumonia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]

Overview

In 1925, G. F. LAUGHLEN, M.D. was the first physician to describe lipoid pneumonia. He first interacted with the disease by routine autopsy at the Toronto, Ontario hospital for sick children. He described grayish red nodules at the autopsy with three types of exudates, found out mononuclear cells which were unexpected in the exudates. In 1949 McDonald et al described endogenous lipoid pneumonia for the first time. He observed so-called "obstructive pneumonia" in patients with lung neoplasms.

Historical Perspective

Discovery

Important landmark

Following are important landmark events that shows how aspiration pneumonia became an important entity of critical care:[4][5][3][6][7][8]

Year Events
460 BC–380 BC Hippocrates described pneumonia.
1138–1204 AD Maimonides wrote about pneumonia as "The basic symptoms which occur in pneumonia and which are never lacking are as follows: acute fever, sticking pleuritic pain in the side, short rapid breaths, serrated pulse, and cough."
1875 Edwin Klebs identified bacteria in the airways of individuals who died from pneumonia.
1848 Carl Friedländer identified the two common bacteria such as Streptococcus pneumoniae and Klebsiella pneumoniae that cause pneumonia.
1893 Veillon was first to write about the role of anaerobic bacteria in aspiration pneumonia.
1896 Roentgen described x-rays.
1918 Sir William Osler, known as "the father of modern medicine," appreciated the morbidity and mortality of pneumonia, describing it as the "captain of the men of death."
1927 Smith was first to clearly show anaerobic bacterial growth in animal models suffered from aspiration pneumonia.
1929 Drinker and Shaw announced the invention of the iron lung during the
 polio epidemic.
1985 Specimens collected from patients with aspiration pneumonia were vastly cultured and it was called anaerobic bandwagon.

Lipoid pneumonia outbreak

{{#ev:youtube|https://www.youtube.com/watch?v=BtKbUpKeU_Q%7C500}}

References

  1. Laughlen GF (July 1925). "Studies on Pneumonia Following Naso-Pharyngeal Injections of Oil". The American Journal of Pathology. 1 (4): 407–414.1. PMC 1931653. PMID 19969662.
  2. McDONALD JR, HARRINGTON SW, CLAGETT OT (1949). "Obstructive pneumonitis of neoplastic origin; an interpretation of one form of so-called atelectasis and its correlation according to presence of absence of sputum". J Thorac Surg. 18 (1): 97–112, disc., 122. PMID 18110247.
  3. 3.0 3.1 Marik PE, Careau P (1999). "The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study". Chest. 115 (1): 178–83. PMID 9925081.
  4. Japanese Respiratory Society (2009). "Aspiration pneumonia". Respirology. 14 Suppl 2: S59–64. doi:10.1111/j.1440-1843.2009.01578.x. PMID 19857224.
  5. Almirall J, Cabré M, Clavé P (2012). "Complications of oropharyngeal dysphagia: aspiration pneumonia". Nestle Nutr Inst Workshop Ser. 72: 67–76. doi:10.1159/000339989. PMID 23052002.
  6. Cordier JF, Cottin V (2013). "Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis". Eur Respir J. 42 (4): 916–23. doi:10.1183/09031936.00027913. PMID 23598958.
  7. Shi X, Zheng J, Yan T (2018). "Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia". J Mol Model. 24 (4): 79. doi:10.1007/s00894-018-3613-z. PMID 29500665.
  8. Shen CF, Wang SM, Ho TS, Liu CC (2017). "Clinical features of community acquired adenovirus pneumonia during the 2011 community outbreak in Southern Taiwan: role of host immune response". BMC Infect Dis. 17 (1): 196. doi:10.1186/s12879-017-2272-5. PMC 5341368. PMID 28270104.
  9. "Outbreak of Electronic-Cigarette–Associated Acute Lipoid Pneumonia — North Carolina, July–August 2019 | MMWR".
  10. "Outbreak of Electronic-Cigarette–Associated Acute Lipoid Pneumonia — North Carolina, July–August 2019 | MMWR".
  11. "CDC vaping illness investigation: Vitamin E acetate linked to THC may be to blame - CNN".

Template:WH Template:WS